Fundraisings and IPOs

Date: 2012-01-20

Type of information: Fundraising

Company: Pronota (Belgium)

Investors: LSP (The Netherlands) - Gimv (Belgium) - Biotech Fund Flanders (Belgium) - KBC Private Equity  (Belgium) - Johnson & Johnson Development Corporation (USA) - VIB (Belgium) - MP Healthcare (USA) - MedSciences Capital (The Netherlands)
a com­pany founder

Amount: € 3.7 mil­lion

Funding type: series C financing round

Planned used:

The pro­ceeds will be used to com­plete the pro­tein bio­marker val­i­da­tion stud­ies for Pronota’s inno­v­a­tive diag­nos­tic prod­ucts in its preeclamp­sia, ovar­ian can­cer, sep­sis and cardio-renal pro­grams.

Others:

Pronota has closed a Series C financ­ing, rais­ing € 3.7 mil­lion from its exist­ing investors. In addi­tion, Pronota announced that Nick McCooke is step­ping down as CEO and board mem­ber to pur­sue oppor­tu­ni­ties closer to his home base in the UK after nearly 6 years as CEO. He is being replaced by Katleen Verleysen, pre­vi­ously COO. At the same time, John Berriman is step­ping down as chair­man to be replaced by Rudy Dekeyser, man­ag­ing direc­tor of VIB.

Therapeutic area: Cancer - Oncology - Infectious diseases

Is general: Yes